Bevacizumab+chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: a randomized phase II trial—PRODIGE 20 study results

BACKGROUND: Metastatic colorectal cancer frequently occurs in elderly patients. Bevacizumab in combination with front line chemotherapy (CT) is a standard treatment but some concern raised about tolerance of bevacizumab for these patients. The purpose of PRODIGE 20 was to evaluate tolerance and effi...

Descripción completa

Detalles Bibliográficos
Autores principales: Aparicio, T, Bouché, O, Taieb, J, Maillard, E, Kirscher, S, Etienne, P -L, Faroux, R, Khemissa Akouz, F, El Hajbi, F, Locher, C, Rinaldi, Y, Lecomte, T, Lavau-Denes, S, Baconnier, M, Oden-Gangloff, A, Genet, D, Paillaud, E, Retornaz, F, François, E, Bedenne, L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5834151/
https://www.ncbi.nlm.nih.gov/pubmed/29045659
http://dx.doi.org/10.1093/annonc/mdx529

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5834151/
https://www.ncbi.nlm.nih.gov/pubmed/29045659
http://dx.doi.org/10.1093/annonc/mdx529

Ejemplares similares